Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
In recent years, the PD-1/PD-L1 axis blockade has become a very promising therapy with significant clinical benefits for multiple tumor types. However, some patients still do not respond sufficiently to PD-1/PD-L1 targeted monotherapy. Therefore, investigating the mechanism of PD-1 blockade resistan...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954840/ https://www.ncbi.nlm.nih.gov/pubmed/32021257 http://dx.doi.org/10.2147/OTT.S239398 |